Article Versions Notes

Tang Y-J, Chang JW-C, Chang C-F, Huang C-Y, Yang C-T, Kuo C-HS, Fang Y-F, Hsu P-C, Wu C-E. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients. Cancers. 2022; 14(20):5095. https://doi.org/10.3390/cancers14205095

Tang, Yan-Jei, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Ping-Chih Hsu, and Chiao-En Wu. 2022. "Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients" Cancers 14, no. 20: 5095. https://doi.org/10.3390/cancers14205095

Tang, Y.-J., Chang, J. W.-C., Chang, C.-F., Huang, C.-Y., Yang, C.-T., Kuo, C.-H. S., Fang, Y.-F., Hsu, P.-C., & Wu, C.-E. (2022). Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients. Cancers, 14(20), 5095. https://doi.org/10.3390/cancers14205095